Extrauterine growth restriction at discharge · preterm or low birth weight infants
High showed no clear difference in extrauterine growth restriction at discharge compared with standard volume of fortified human milk or preterm formula (low certainty).
1 finding from 1 review
Necrotising enterocolitis · preterm or low birth weight infants
It is very uncertain whether high changes necrotising enterocolitis compared with standard volume of fortified human milk or preterm formula (very low certainty).
1 finding from 1 review
Weight gain · preterm or low birth weight infants
1 finding from 1 review
Linear growth (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Growth: head circumference (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Extrauterine growth restriction at discharge · preterm or low birth weight infants
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · children or adults with hemophilia A
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in AJBR compared with pegylated liposome FVIII formulation (low certainty).
1 finding from 1 review
ABR · children or adults with hemophilia A
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in ABR compared with pegylated liposome FVIII formulation (low certainty).
1 finding from 1 review
Any reported adverse effects · children or adults with hemophilia A
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
1 finding from 1 review
Relapse during intervention defined as admission to inpatient therapeutic care, remain wasted, and dropouts during intervention period · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
Standard ready‐to‐use therapeutic food (RUTF) leads to lower relapse during intervention defined as admission to inpatient… compared with RUTF using an alternative formulation (high certainty).
1 finding from 1 review
Mortality during intervention · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
Standard ready‐to‐use therapeutic food (RUTF) showed no clear difference in mortality during intervention compared with RUTF using an alternative formulation (moderate certainty).
1 finding from 1 review
Rate of weight gain (g/kg/day) · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
1 finding from 1 review
Recovery during intervention defined as weight gain ≥ 15% in relation to baseline weight, absence of complications and oedema, and MUAC > 110 mm in 2 studies; MUAC > 12.4 cm without oedema in 1 study; WHZ ≥ 80% for two consecutive visits in 1 stud... · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
Standard ready‐to‐use therapeutic food (RUTF) showed no clear difference in recovery during intervention defined as weight gain ≥ 15% in… compared with RUTF using an alternative formulation (high certainty).
1 finding from 1 review
Number of episodes of regurgitation or vomiting per day · Formula‐fed healthy term infants up to 6 months of age with gastro‐oesophageal reflux
1 finding from 1 review